In this study Denosumab significantly reduced or eliminated RANK-positive tumour giant cells and also reduced the relative content of proliferative, densely cellular tumour stromal cells, replacing them with nonproliferative, differentiated, and densely woven new bone. This evidence concerns the gene TNFRSF11A and neoplasm.